Protembis Secures €20 Million Financing from EIB to Advance ProtEmbo® Cerebral Protection System for Safer Cardiac Interventions

Recently, Protembis received 20 million euros in support from the EIB (European Investment Bank).This follows the €30 million Series B financing announced in March this year, which completed the pivotal trial recruitment for the ProtEmbo® cerebral protection system's Investigational Device Exemption (IDE). It marks another financing round for Protembis within the year.

It is reported that Protembis, a medical device developer, aims to minimize the risk of particle migration to the brain during interventional cardiac procedures. The company is currently developing an innovative cerebral protection system, intending to incorporate the ProtEmbo® system into every interventional procedure with a risk of neurological damage, thereby fundamentally enhancing the safety of such surgeries.

Notably, Protembis has also appointed Dr. Keith D. Dawkins, an interventional cardiologist with over 20 years of experience, to its board of directors. Dr. Dawkins has served as a Fulbright Scholar at Stanford University, as the president of the British Cardiovascular Intervention Society, and as the Chief Medical Officer of Shockwave, a company dedicated to using technological interventions to modulate calcium levels in the vascular system.

"I have always believed that in transcatheter aortic valve replacement, protecting the brain from any new injury is crucial," said Dr. Dawkins after joining the board of Protembis. "The ProtEmbo system and clinical trial design are uniquely innovative, and I believe they will revolutionize the field of cerebral embolic protection, addressing some significant issues currently troubling the medical community."

Technical Advantages

The ProtEmbo® Brain Protection System developed by Protembis represents the cutting-edge technology in safeguarding the brain from embolic material damage during transcatheter aortic valve replacement (TAVR) procedures. Delivered through the left radial artery, the system provides physicians with an ideal access point to avoid interference with TAVR devices delivered via the femoral artery, reflecting Protembis' innovative design thinking and deep understanding of patient needs.

ProtEmboNot only can it minimize the risk of cerebrovascular events associated with transcatheter aortic valve replacement (TAVR), but it can also reduce the risks associated with many other interventional and surgical procedures.ProtEmboAdvantages include:

• Smaller Profile, entering the aortic arch through the left radial artery (6FR guiding sheath);

• The product is simple, fast, and reliable to use.

• Full coverage of the three branches of the aorta

• Deflect thrombus microparticles larger than 60 nanometers, directing them to flow into the descending aorta.

• Suitable for Aortic Arches with Different Physiological Structures

• Coated with heparin, featuring enhanced biocompatibility.

• Through the left radial artery, without interfering with the TAVR catheter or TAVR procedure-related accessories.

During the transcatheter aortic valve replacement (TAVR) procedure, the ProtEmbo® cerebral protection system deflects thrombotic material, preventing it from entering the cerebral vascular circulation. It is inserted through the left radial artery sheath, capable of covering the three head vessels leading to the brain. With a pore size of 60 micrometers and coated with heparin, it effectively prevents thrombotic material from reaching the brain.

Future Prospects

By effectively deflecting thrombotic material, ProtEmbo® significantly reduces the clinical stroke rate by up to 9% after TAVR procedures, decreases the risk of silent cerebral infarction in almost all TAVR patients, and lowers the risks of cognitive decline, future strokes, mortality, and dementia.Given the widespread application of TAVR procedures and the importance of cerebral protection in cardiac surgery, the ProtEmbo® system holds significant potential for future cardiovascular treatments.Currently, the ProtEmbo® system is undergoing clinical investigation and is expected to have a revolutionary impact on the treatment of cardiovascular diseases once it receives approval for commercial use.

——【END】——